Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics [0.03%]
作为癌症治疗手段的管蛋白聚合抑制剂一期临床试验
Ahmed Kamal,Rahaman Shaik,Prasanna Anjaneyulu Yakkalaa
Ahmed Kamal
Introduction: Microtubules are essential to cancer therapy as key cytoskeletal components that regulate cell division, intracellular transport, and mitotic spindle formation. Tubulin polymerization inhibition is a critica...
Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia? [0.03%]
选择性降氧素受体拮抗剂治疗失眠症显成效？
Sheila A Doggrell
Sheila A Doggrell
Insomnia is common. Seltorexant (JNJ-42847922), a selective orexin-2 receptor antagonist, was originally trialed in major depression. In a repurposing, seltorexant has been tested in a phase 2b trial for insomnia. This trial represents a ne...
Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings [0.03%]
IMNN-001在卵巢癌上皮性肿瘤中的应用潜力：临床发现评估
Premal H Thaker,Stacy R Lindborg,Ana Limon et al.
Premal H Thaker et al.
Introduction: IMNN-001 is designed for local and durable delivery of a pluripotent anti-tumor cytokine, IL-12, using an expression plasmid and a synthetic lipopolymer delivery system. IMNN-001, delivered intraperitoneally...
Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 drug evaluation [0.03%]
司美lässig(SUVN-G3031)，一种组胺H₃受体拮抗剂，有望治疗嗜睡症：Ⅱ期药物评估
Ramakrishna Nirogi,Anil Shinde,Ramkumar Subramanian et al.
Ramakrishna Nirogi et al.
Introduction: Narcolepsy is a debilitating chronic neurological disorder, and currently, there is no cure. Activation of the histaminergic system through the blockade of histamine 3 (H3) autoreceptors promotes wakefulness...
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials [0.03%]
哮喘治疗中的实验性靶向警报肽药物：I期和II期临床试验的启示及进展
Maral Ranjbar,Christiane E Whetstone,Ravneet K Hansi et al.
Maral Ranjbar et al.
Introduction: Asthma is a chronic and heterogeneous airway disease in which epithelial-derived cytokines - TSLP, IL-33, and IL-25-act as upstream drivers of inflammation. Over the past decade, these alarmin cytokines have...
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress [0.03%]
Kat6抑制剂治疗实体瘤的研究进展：从临床前到早期临床阶段
Toru Mukohara
Toru Mukohara
Introduction: KAT6A and its paralog KAT6B (KAT6) are part of the MYST family of histone acetyltransferases. KAT6 is involved in regulating multiple cellular processes by acetylating different lysine residues on histone H3...
Experimental p38 MAPK inhibitors for the treatment of urological cancers: observations from early clinical trials [0.03%]
针对尿路上皮癌p38丝裂原活化蛋白激酶抑制剂的临床前与临床研究
Charalampos Fragkoulis,Panagiotis Velissarios Stamatakos,Nikolaos Kontolatis et al.
Charalampos Fragkoulis et al.
Introduction: Adopted response in signals consists a cornerstone ability of cancer cells resulting in their survival and proliferation. Molecular pathways of MAPK and specifically p38/SAPKs regulate such responses. Recent...
Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I study [0.03%]
CTP55与原研药secukinumab的药代动力学和安全性的比较：一项三臂、随机、双盲、单次给药、多中心Ⅰ期临床试验
Tomoko Hasunuma,Michio Yagi,Noboru Nakamichi et al.
Tomoko Hasunuma et al.
Background: This first-in-human study compared the pharmacokinetics, safety, and immunogenicity of candidate biosimilar CT-P55 to both European Union (EU)-approved and United States (US)-licensed secukinumab in healthy pa...
Triple negative breast cancer: what clinical progress have we seen in the last 5 years? [0.03%]
三阴性乳腺癌的临床治疗进展：过去五年带来了什么？
Daniel S Peiffer,Maeve A Hennessy,Rita Nanda
Daniel S Peiffer
Introduction: Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It accounts for ~15...